Female patient with p.Leu861Gln substitution showed PD-L1 expression on 40% of tumor cells and in immune cells (2% of tumor area) in both assays, while male patient with p.Gly719X substitution presented 90% (22C3) and 40% (SP142) of tumor cells with PD-L1 expression (in this patient 4% of tumor area showed immune cells with PD-L1 expression). This evidence concerns the gene CD274 and neoplasm.